The Impact of Exogenous Insulin Input on Calculating Hepatic Clearance Parameters. (July 2022)

• Record Type: Journal Article
• Authors: McHugh, Alexander D.; Chase, J. Geoffrey; Knopp, Jennifer L.; Ormsbee, Jennifer J.; Kulawiec, Diana G.; Merry, Troy L.; Murphy, Rinki; Shepherd, Peter R.; Burden, Hannah J.; Docherty, Paul D.
• Is Part Of: Journal of diabetes science and technology. Volume 16:Number 4(2022)
• Page Start: 945
• Page End: 954
• Publication Date: 2022-07
• Subjects: insulin kinetics -- hepatic clearance -- identification -- IVGTT -- assay error -- insulin modified -- identification error; Diabetes -- Periodicals; Medical technology -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462005
• DOI: 10.1177/1932296820986878
• Languages: English
• ISSNs: 1932-2968

Abstract

Objective: Model-based metabolic tests require accurate identification of subject-specific parameters from measured assays. Insulin assays are used to identify insulin kinetics parameters, such as general and first-pass hepatic clearances. This study assesses the impact of intravenous insulin boluses on parameter identification precision. Method: Insulin and C-peptide data from two intravenous glucose tolerance test (IVGTT) trials of healthy adults ( N = 10 × 2; denoted A and B), with (A) and without (B) insulin modification, were used to identify insulin kinetics parameters using a grid search. Monte Carlo analysis ( N = 1000) quantifies variation in simulation error for insulin assay errors of 5%. A region of parameter values around the optimum was identified whose errors are within variation due to assay error. A smaller optimal region indicates more precise practical identifiability. Trial results were compared to assess identifiability and precision. Results: Trial B, without insulin modification, has optimal parameter regions 4.7 times larger on average than Trial A, with 1-U insulin bolus modification. Ranges of optimal parameter values between trials A and B increase from 0.04 to 0.12 min -1 for hepatic clearance and from 0.07 to 0.14 for first-pass clearance on average. Trial B's optimal values frequently lie outside physiological ranges, further indicating lack of distinct identifiability. Conclusions: A small 1-U insulin bolus improves identification of hepatic clearance parameters by providing a smaller region of optimal parameter values. Adding an insulin bolus in metabolic tests can significantly improve identifiability and outcome test precision. Assay errors necessitate insulin modification in clinical tests to ensure identifiability and precision.